Featured in “day 1″ at the ASCO annual meeting

Saturday was never going to be a major day for prostate cancer at the annual meeting of the American Society for Clinical Oncology (ASCO) here in Chicago. … READ MORE …

EMEA approves Prolia for marketing in Europe

According to a report from Reuters and a media release on the Amgen web site, the European Medicines Agency (EMEA) has approved denosumab (Prolia®) for marketing in Europe. … READ MORE …

Amgen files new drug application for denosumab

According to a company media release issued last Friday, Amgen has filed a second new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval of denosumab (a RANK-L inhibitor to be known commercially as Prolia®). … READ MORE …

Prostate cancer news reports: Tuesday, April 20, 2010

In today’s news reports we note new articles dealing with:

  • Biopsy protocols, patient selection, and focal therapy
  • Tertiary Gleason pattern 4/5 and risk for progression post-RP
  • Evolving data on the uses of bisphosphonates and denosumab
  • SKIs in treatment of advanced forms of prostate cancer … READ MORE …

Denosumab: “better” than zoledronate?

A media release issued yesterday by Amgen claims that denosumab “demonstrated superiority” over zoledronate (Zometa) in a randomized, multi-center, Phase III clinical trial in prostate cancer patients with bone metastases. … READ MORE …

FDA advisory committee splits on approval of denosumab

The FDA’s advisory panel has apparently recommended approval of denosumab, but only for some of the indications that were being  requested by the manufacturer. … READ MORE …

A critical week for denosumab

Tomorrow (Thursday) an advisory committee to the US Food and Drug Administration (FDA) meets to decide whether to recommend approval of Amgen’s new RANK-L inhibitor, denosumab, which offers an entirely new mechanism for the reduction of the risk of fractures and other skeletal related events (SREs) caused by long term hormone therapy (both in patients with breast cancer and those with prostate cancer). … READ MORE …

Is denosumab “better” than Zometa at preventing skeletal events?

Amgen, the developer of denosumab (also known as RANK-L) has released data today from a head-to-head trial of their drug vs. zoledronate (Zometa) in the management of patients with advanced breast cancer and bone metastases. … READ MORE …

AUA report and update no. 2: Sunday, April 26, 2009

Two important papers presented this afternoon addressed data on the use of toremifene and denosumab on the bones of men receiving treatment with androgen deprivation therapy (ADT). … READ MORE …

The Thursday news reports: March 19, 2009

There are six new reports in today’s news, of which the most immediately important would seem to be:

  • How men manage their “fear” while on active surveillance
  • “Cancer anxiety” and early use of hormonal therapy
  • Approval for a Phase III clinical trial of MDV3100 … READ MORE …

Thursday’s news reports: February 19, 2009

Today’s important news reports address:

  • 5- and 7-year survival data following iodine-125 permanent implant brachytherapy
  • Risks associated with low levels of lymphocyte apoptosis in patients receiving radiation therapy
  • Stiffening of the large arteries in men receiving antiandrogen therapy
  • The status of the toremifene and denosumab applications for approval for marketing in the USA … READ MORE …
Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers